

## 6. Literaturverzeichnis

1. Abraha HD, Fuller LC, Du Vivier AWP, Higgins EM, Sherwood RA: Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. *Br J Dermatol* 137: 381-385 (1997).
2. Allore RJ, Friend WC, O'Hanlon D, Neilson KM, Baumal R, Dunn RJ, Marks A: Cloning and expression of the human S 100 beta gene. *J Biol Chem* 265: 15537-15543 (1990).
3. Aubin F, Chtourou M, Teyssier JR, Laubriet A, Mouglin CH, Blanc D, Humbert PH: The detection of tyrosinase mRNA in the peripheral blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk and survival. *Melanoma Res* 10: 113-118 (2000).
4. Battayani Z, Grob JJ, Xerri L, Noe C, Zarour H, Houvaenaghel G, Delpero JR, Birnbaum D, Hassoun J, Bonerandi JJ: Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. *Arch Dermatol* 131: 443-447 (1995).
5. Bogdahn U, Apfel R, Hahn M, Gerlach M, Behl C, Hoppe J, Martin R: Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. *Cancer Res* 49: 5358-5363 (1989).
6. Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, Buettner R: MIA, a novel serum marker for progression of malignant melanoma. *Cancer Res* 57: 3149-3153 (1997).
7. Bosserhoff AK, Kondo S, Moser M, Dietz U, Copeland NG, Gilbert DJ, Jenkins NA, Buettner R, Sandell LJ: The mouse MIA/CD-RAP gene: structure, chromosomal localization and expression in cartilage and chondrosarcoma. *Dev Dyn* 208: 516-525 (1997).

8. Bosserhoff AK, Golob M, Buettner R, Landthaler M, Hein R: MIA, Biologische Funktionen und klinische Relevanz beim malignen Melanom. *Hautarzt* 49: 762-769 (1998).
9. Boyle P, Maisonneuve P, Dore JF: Epidemiology of malignant melanoma. *Br Med Bull* 51: 523-547 (1995).
10. Boyum A: Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. *Scand J Clin Lab Invest* 21 (suppl. 97): 77-89 (1968).
11. Braun-Falko O, Landthaler M, Hölzel D, Konz B, Schmoeckel C: Klassifizierung, Diagnose und Differentialdiagnose maligner Melanome. *Chir* 57: 593-600 (1986).
12. Breslow A: Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. *Ann Surg*: 172-902 (1970).
13. Bröcker E, Bastian B, Dummer W: Von der immunologischen zur molekularen Melanomdiagnostik. *Z Hautkrankh* 72: 168-172 (1997).
14. Brossart P, Keilholz U, Willhauck M, Scheibenbogen C, Möhler T, Hunstein W: Hematogenous spread of malignant melanoma cells in different stages of disease. *J Invest Dermatol* 101: 887-889 (1993).
15. Brossart P, Schmier JW, Kruger S, Willhauck M, Scheibenbogen C, Mohle T, Keilholz U: A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. *Cancer Res.* 55: 4065-4068 (1995).
16. Buer J, Probst M, Franzke A, Duensing S, Haindl J, Volkenandt M, Wittke F, Hoffmann R, Ganser A, Atzpodien J: Elevated serum levels of S100 and survival in metastatic malignant melanoma. *Br J Cancer* 75(9): 1373-1376 (1997).

17. Burchill SA, Bradbury FM, Smith B, Lewis IJ, Selby P: Neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosinase hydroxylase mRNA. *Int J Cancer* 57: 671-674 (1994).
18. Burg G, Nestle F, Dummer R: Neue Erkenntnisse zum malignen Melanom. *Deutsches Ärzteblatt* 94: A-1191 (1997).
19. Carey TE, Takahashi T, Resnick LA, Oettgen HF, Old LJ: Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. *Proc Natl Acad Sci USA* 73: 3278-3282 (1976).
20. Carrillo E, Prados J, Melguizo C, Marchal JA, Velez C, Serrano S, Boulaiz H, Merida JA, Aranega A: Reverse transcriptase-polymerase chain reaction detection of circulating tumor cells in patients with melanoma: Correlation with clinical stage, tumor thickness and histological type. *Path Inter* 52: 294-299 (2002).
21. Cho KH, Hashimoto K, Taniguchi Y, Pietruk T, Zarbo RJ, An T: Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunits. *Cancer* 66: 765-771 (1990).
22. Chomczynski P, Sacchi N: Single-step method for RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 162: 156-159 (1987).
23. Clapham D: Calcium Signaling. *Cell* 80: 259-268 (1995).
24. Clark WH Jr: A classification of malignant melanoma in man correlated with histogenesis and biologic behavior. In: Montagna W, Hu F (eds) *Advances in Biology of the Skin, Vol 8, The Pigmentary System*. Pergamon Press, London, p 621 (1967).
25. Coulie PG, Brichard V, van Pel A, Wölfel T, de Plaen E, Lurquin, Szikora JP, Renauld JC, Boon T: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. *J Exp Med* 180: 35-42 (1994).

26. Cross NCP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM: Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. *Blood* 82: 1929-1936 (1993).
27. Curry BJ, Smith MJ, Hersey P: Detection and quantitation of melanoma cells in the circulation of patients. *Melanoma Res* 6: 45-54 (1996).
28. Curry BJ, Myers K, Hersey P: Polymerase chain reaction detection of melanoma cells in the circulation: Relation to clinical stage, surgical treatment, and recurrence from melanoma. *J Clin Oncol* 16: 1760-1769 (1998).
29. Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS: Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. *J Clin Oncol* 12: 475-482 (1994).
30. Deichmann M, Benner A, Bock M, Jackel A, Uhl K, Waldmann V, Naher H: S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. *J Clin Oncol* 17(6): 1891-1896 (1999).
31. Dietz UH, Sandell LJ: Cloning of a retinoic acid-sensitive mRNA expressed in cartilage and during chondrogenesis. *J Biol Chem* 271: 3311-3316 (1996).
32. Donato R: Perspectives in S-100 protein biology. *Cell Calcium* 12: 713-726 (1991).
33. Eberle J, Garbe C, Wang N, Orfanos CE: Incomplete expression of the tyrosinase gene family (Tyrosinase, TRP-1, and TRP-2) in human malignant melanoma cells in vitro. *Pigment Cell Res* 8: 307-313 (1995).
34. Elder DE: Skin cancer; Melanoma and other specific nonmelanoma skin cancers. *Cancer* 75: 245-256 (1995).

35. Ercolani L, Florence B, Denaro M, Alexander M: Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene. *J Biol Chem* 30: 15335-15341 (1988).
36. Fagnart OC, Sindic CJM, Laterre C: Particle counting immunoassay of S100 protein in serum: Possible relevance in tumors and ischemic disorders of the central nervous system *Clin Chem* 34: 1387-1391 (1988).
37. Farthmann B, Eberle J, Krasagakis K, Gstöttner M, Wang N, Bisson S, Orfanos CE: RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: Evaluation strategy and correlation with known prognostic markers in 123 patients. *J Invest Dermatol* 110: 263-267 (1998).
38. Fidler IJ: Metastasis: quantitative analysis of distribution and fate of tumor embolilabeled with <sup>125</sup>I-5-iodo-2'-deoxyuridine. *J Natl Cancer Inst.* 45(4): 773-782 (1970).
39. Fidler IJ: Host and tumour factors in cancer metastasis. *Eur J Clin Invest* 20: 481-486 (1990).
40. Fidler IJ: Cancer metastasis. *Br Med Bull* 47: 157-177 (1991).
41. Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg I, Austen KF: *Clinical Dermatology*. McGraw-Hill, Inc., New York, St. Louis, San Francisco, 4. Auflage, 261-284 (1993).
42. Foss AJE, Guille MJ, Occleston NL, Hykin PG, Hungerford JL, Lightman SL: The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. *Br J Cancer* 72: 155-159 (1995).
43. Garbe C, Bertz J, Orfanos CE: Malignes Melanom: Zunahme von Inzidenz und Mortalität in der Bundesrepublik Deutschland. *Z Hautkr*:1751-1764 (1986).

44. Garbe C, Blum A: Epidemiology of cutaneous melanoma in Germany and worldwide. *Skin Pharmacol Appl Skin Physiol* 14: 280-290 (2001).
45. Garbe C, Büttner P, Bertz J, Burg G, d'Hoedt B, Drepper H, Guggenmoos-Holzmann I, Lechner W, Lippold A, Orfanos CE, Peters A, Rassner G, Stadler R, Sröbel W: Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. *Cancer* 75: 2484-2491 (1995a).
46. Garbe C, Büttner P, Bertz J, Burg G, d'Hoedt B, Drepper H, Guggenmoos-Holzmann I, Lechner W, Lippold A, Orfanos CE, Peters A, Rassner G, Stadler R, Sröbel W: Primary cutaneous melanoma. Prognostic classification of anatomic location. *Cancer* 75: 2492-2498 (1995b).
47. Garbe C, McLeod GR, Buettner PG: Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. *Cancer* 89: 1269-1278 (2000).
48. Garbe C, Paul A, Kohler-Späth H, Ellwanger U, Stroebel W, Schwarz M et al.: Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: Recommendations for an effective follow-up strategy. *J Clin Oncol* 21: 520-529 (2003b).
49. Garbe C, Schadendorf D: Malignes Melanom- neue Daten und Konzepte zur Nachsorge. *Deutsches Ärzteblatt* 100: C1409-1412 (2003a).
50. Garbe C, Schaumburg-Lever G: Klinik und Histologie des malignen Melanoms. In: Garbe C, Dummer R, Kaufmann R, Tilgen W: *Dermatologische Onkologie*. Springer Verlag Berlin, Heidelberg, New York, 262-264 (1997).
51. Garbe C, Stadler R, Orfanos CE: Lokalrezidive und Metastasierung bei dünnen malignen Melanomen ( $\leq 1$  mm). *Hautarzt* 40: 337-343 (1989).
52. Gassen HG, Bertram S: *Gentechnische Methoden*. Gustav Fischer Verlag, Stuttgart, Jena, New York (1991).

53. Gaynor R, Irie R, Morton D, Herschman H: S100 protein is present in cultured human melanomas. *Nature* 286: 400-401 (1980).
54. Georgieva J, Milling A, Orfanos CE, Geilen CC: Magnetic bead RT-PCR: establishment of a new method for detecting circulating melanoma cells. *Melanoma Res* 12: 309-317 (2002).
55. Gerhard M, Juhl H, Kalthoff H, Schreiber HW, Wagener C, Neumaier M: Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. *J Clin Oncol* 12: 725-729 (1994).
56. Ghanem G, Loir B, Sales F, Pector JC, Ewalenko P, Kerger J, Lienard D, Lejuene F, Deraemaeker F, Frühling J: Serum protein S-100 is a useful marker in metastatic melanoma. *Melanoma Res* 7: S55 (1997).
57. Ghossein RA, Coit D, Brennan M, Zhang ZF, Wang Y, Bhattacharya S, Houghton A, Rosai J: Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. *Clin Cancer Res* 4: 419-428 (1998).
58. Giebel LB, Strunk KM, Spritz RA: Organization and nucleotide sequence of the human tyrosinase gene and a truncated tyrosinase-related segment. *Genomics* 9: 435-445 (1991).
59. Gläser R, Rass K, Seiter S, Hauschild A, Christophers E, Tilgen W: Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. *J Clin Oncol* 15: 2818-2825 (1997).
60. Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmüller D: Clinical significance of serum S100 in metastatic malignant melanoma. *Eur J Cancer* 31: 924-928 (1995).
61. Hanekom GS, Stubbings HM, Johnson CA, Kidson SH: The detection of circulating melanoma cells correlates with tumour thickness and ulceration but is not predictive of metastasis for patients with primary melanoma. *Melanoma Res* 9: 465-473 (1999).

62. Hauschild A, Engel G, Brenner W, Gläser R, Henze E, Christophers E: Sangtec S-100 $\beta$  is a reliable serum marker for metastatic melanoma. *Melanoma Res* 7: S55 (1997).
63. Hauschild A, Michaelsen J, Brenner W, Rudolph P, Gläser R, Henze E, Christophers E: Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. *Melanoma Res* 9: 155-161 (1999).
64. Hein R, Gummer M, Messer G, Plewig G: Klinische Typen des malignen Melanoms. *Manual maligne Melanome*: 7-10 (2000).
65. Heimdal K, Hannisdal E, Gundersen S: Regression analysis of prognostic factors in metastatic malignant melanoma. *Eur J Cancer Clin Oncol* 25: 1219-1223 (1989).
66. Henze G, Dummer R, Joller-Jemelka H, Böni R, Burg G: Serum S100 – a marker for disease monitoring in metastatic melanoma. *Dermatology* 194: 208-212 (1997).
67. Herlyn M, Koprowski H: Melanoma antigens: immunological and biological characterization and clinical significance. *Ann Rev Immunol* 6: 283-308 (1988).
68. Hoon DSB, Wang Y, Dale PS; Conrad AJ, Schmid P, Garrison D, Kuo C, Foshag LJ, Nizze AJ, Morton DL: Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. *J Clin Oncol* 13: 2109-2116 (1995).
69. Isobe T, Okuyama T: The amino acid sequence of S 100 protein (PAP-1b) and its relationship to calcium binding proteins. *Eur J Biochem* 89: 379-388 (1978).
70. Jäckel A, Deichmann M, Waldmann W, Bock M, Näher H: S100beta Protein im Serum als Tumormarker beim malignen Melanom- Aktueller Kenntnisstand und klinische Erfahrungen. *Hautarzt* 50: 250-256 (1999).
71. Johnson PWM, Burchill SA, Selby PJ: The molecular detection of circulating tumour cells. *Br J Cancer* 72: 268-276 (1995).



72. Jung FA, Buzaid AC, Ross M, Woods KV, Grimm EA: Detection of melanoma cells in peripheral blood using reverse transcription polymerase chain reaction assay for tyrosinase mRNA. *Cancer Surv* 26: 251-265 (1996).
73. Jung FA, Buzaid AC, Ross MI, Woods KV, Lee JJ, Albitar M, Grimm EA: Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. *J Clin Oncol* 15: 2826-2831 (1997).
74. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 53: 457-481 (1958).
75. Katz AE, Olsson CA, Raffo AJ, Cama C, Perlman H, Seaman E, O'Tool KM, Mc Mahon D, Benson MC, Buttyan R: Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. *Urology* 15: 765-775 (1994).
76. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. *Proc Natl Acad Sci USA* 91: 3515-3519 (1994).
77. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yanelli JR, Adema GJ, Miki T, Rosenberg SA: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. *Proc Natl Acad Sci USA* 91: 6458-6462 (1994).
78. Kawasaki ES, Clark SS, Coyne MY, Smith SD, Champlin R, Witte ON, McCormick FP: Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. *Proc Natl Acad Sci USA* 85: 5698-5702 (1988).
79. Keilholz U, Willhauck M, Rimoldi D, Brasseur F, Dummer W, Rass K, de Vries T, Blaheta J, Voit C, Lethe B, Burchill S: Reliability of reverse transcription-polymerase chain reaction (RT-PCR)-based assays for the detection of circulating tumour cells: a quality-

assurance initiative of the EORTC melanoma cooperative Group. *Eur J Cancer* 34: 750-753 (1998).

80. Kligman D, Hilt DC: The S 100 protein family. *Trends Biochem Sci* 13: 437-443 (1988).

81. Koehler MN, Bosserhoff A, von Beust G, Bauer A, Blesch A, Buettner R, Schlegel J, Bogdahn U, Schmid M: Assignment of the human melanoma inhibitory activity gene (MIA) to 19q13.32-q1913.33 by fluorescence in situ hybridization (FISH). *Genomics* 35: 265-267 (1996).

82. Komeda T, Kukuda Y, Sando T et al.: Sensitive detection of circulating hepatocellular carcinoma cells in peripheral blood. *Cancer* 75: 2214-2219 (1995).

83. Koop S, MacDonald IC, Luzzi K, Schmidt EE, Morris VL, Grattan M, Khokha R, Chambers AF, Groom AC: Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate. *Cancer Res* 55: 2520-2523 (1995).

84. Körner A, Pawelek J: Mammalian tyrosinase catalyses three reactions in the biosynthesis of melanin. *Science* 217: 1163-1165 (1982).

85. Kunter U, Buer J, Probst M, Duensing S, Dallmann I, Grosse J, Kirchner H, Schluepen EM, Volkenandt M, Ganser A, Atzpodien J: Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. *J Natl Cancer Inst* 88: 590-594 (1996).

86. Kwon BS, Haq AK, Pomerantz SH, Halaban R: Isolation and sequence of a cDNA clone for human tyrosinase that maps at the mouse c-albino locus. *Proc Natl Acad Sci USA* 84: 7473-7477 (1987).

87. Lee M-S, Chang K-S, Cabanillas F, Freireich EJ, Trujillo JM, Stass SA: Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. *Science* 237: 175-178 (1987).

88. Mattano LA, Moss TJ, Emerson SG: Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction. *Cancer Res* 52: 4701-4705 (1992).
89. Meier F, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G et al.: Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. *Br J Dermatol* 147: 62-70 (2002).
90. Mellado B, Colomer D, Castel T, Munoz M, , Carballo E, Galan M, Mascaro JM, Vives-Corrans JU, Grau JJ, Estape J: Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: Association with clinical stage and prognosis. *J Clin Oncol* 14: 2091-2097 (1996).
91. Mellado B, Gutierrez L, Castel T, Colomer D, Fontanillas M, Castro J, Estape J: Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. *Clin Cancer Res* 5: 1843-1848 (1999).
92. Mellado B, del Carmen Vela M, Colomer D, Gutierrez L, Castel T, Quinto L, Fontanillas M, Reguart N, Domingo-Domenech JM, Montagut C, Estape J, Gascon P: Tyrosinase mRNA in blood of patients with melanoma treated adjuvant interferon. *J Clin Oncol* 20: 4032-4039 (2002).
93. Miettinen M, Fernandez M, Franssila K, Gatalica Z, Lasota J, Sarlomo-Rikala M: Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. *Am J Surg Pathol* 25: 205-211 (2001).
94. Miliotes G, Lyman GH, Cruse CW, Puleo C, Albertini J, Rapaport D, Glass F, Fenske N, Soriano T, Cuny C, Van Voorhis N, Reintgen D: Evaluation of new putative tumor markers for melanoma. *Ann Surg Oncol* 3: 558-563 (1996).
95. Moore BW: A soluble protein characteristic of the nervous system. *Biochem Biophys Res Comm* 19: 739-744 (1965).

96. Moos TJ, Sanders DG: Detection of neuroblastoma cells in blood. *J Clin Oncol* 8: 736-740 (1990).
97. Moreno JG, Croce CM, Fischer R, Monne M, Vihko P, Mulholland SG, Gomella LG: Detection of hematogenous micrometastasis in patients with prostate cancer. *Cancer Res* 52: 6110-6112 (1992)
98. Mullis KB: The unusual origin of the polymerase chain reaction. *Sci Am* 262: 56-61 (1990).
99. Nadel EM: A Cautionary note to those concerned with circulating cancer cells in the blood. *J Natl Cancer Inst* 29: 1023-1024 (1962).
100. Naito H, Kuzumaki N, Uchino J, Kobayashi R, Shikano T, Ishikawa Y, Matsumoto S: Detection of tyrosinase hydroxylase mRNA and minimal neuroblastoma cells by the reverse transcription-polymerase chain reaction. *Eur J Cancer* 27: 762-765 (1991).
101. Nakajima T, Sato Y, Watanabe S: Immunoelectron microscopical demonstration of S100 protein in epidermal Langerhans cells. *Biomed Res* 3: 226-231 (1982).
102. Newton DR: PCR. Spektrum Akademischer Verlag GmbH, Heidelberg, Berlin, Oxford (1994).
103. Orfanos CE, Jung EG, Rassner G, et al.: Stellungnahme und Empfehlungen der Kommission malignes Melanom der Deutschen Dermatologischen Gesellschaft zur Diagnostik, Behandlung und Nachsorge des malignen Melanoms der Haut. *Hautarzt* 45: 285-291 (1994).
104. Orfanos CE, Garbe C: Therapie der Hautkrankheiten. Springer Verlag, 859 (1995).
105. Orlow SJ, Hearing VJ, Sakai C, Urabe K, Zhou B-K, Silvers WK, Mintz B: Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression. *Proc Natl Acad Sci USA* 92: 10152-10156 (1995).

106. Palmieri G, Strazzullo M, Ascierto PA, Satriano SMR, Daponte A, Castello G: Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. *J Clin Oncol* 17: 304-311 (2003).
107. Palmieri G, Ascierto PA, Perrone F, Satriano SMR, Ottaiano A, Daponte A, Napolitano M, Caraco C, Mozzillo N, Melucci MT, Cossu A, Tanda F, Gallo C, Satriano RA, Castello G: Prognostic value of circulating melanoma cells detect by reverse transcriptase-polymerase chain reaction-. *J Clin Oncol* 21: 767-773 (1999).
108. Pelkey TJ, Frierson JrHF, Bruns DE: Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors. *Clin Chem* 42: 1369-1381 (1996).
109. Peterson LL, Woodward WR, Fletscher WS, Palmquist M, Tucker MA, Illias A: Plasma 5-S-Cysteinyldopa differentiates patients with primery and metastatic melanoma from patients with dysplastic nevus syndrom and normal subjects. *J Am Acad Dermatol* 19: 509-515 (1988).
110. Pittman K, Burchill S, Smith B, Southgate J, Joffe J, Gore M, Selby P: Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. *Ann Oncol* 7: 297-301 (1996).
111. Proebstle TM, Jiang W, Högel J, Keilholz U, Weber L, Voit C: Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors. *Br J Cancer* 82: 118-123 (2000).
112. Redding WH, Coombes RC, Monaghan P, Clink HM, Imrie SF, Dearnaley DP et al.: Detection of micrometastases in patients with primary breast cancer. *Lancet* 3: 1271-1273 (1983).
113. Reinhold U, Lüdtke-Handjery HC, Schnautz S, Kreysel HW, Abken H: The Analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. *J Invest Dermatol* 108: 166-169 (1997).

114. Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, Arnheim N: Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. *Science* 230: 1350-1354 (1985).

115. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Ehrlich HA: Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. *Science* 239: 487 (1988).

116. Sarantou T, Chi DDJ, Garrison DA, Conrad AJ, Schmid P, Morton DL, Hoon DSB: Melanoma-associated antigens as messenger RNA detection markers for melanoma. *Cancer Res* 57: 1371-1376 (1997).

117. Schäfer BW, Wicki R, Engelkamp D, Mattei MG, Heizmann CW: Isolation of a YAC clone covering a cluster of nine S 100 genes on human chromosome 1q21: Rationale for a new nomenclature of the S 100 calcium-binding protein family. *Genomics* 25: 638-643 (1995).

118. Schittek B, Bodingbauer Y, Ellwanger U, Blaheta HJ, Garbe C: Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma. *Br J Derm* 141: 30-36 (1999).

119. Schultz E, Diepgen T, Driesch P: Clinical and prognostic relevance of serum S100B protein in malignant melanoma. *Br J Derm* 138: 426-430 (1997).

120. Schwarze G, Fiedler H: Zur diagnostischen Bedeutung des  $\alpha$ -MSH beim malignen Melanom des Menschen. *Hautarzt* 45: 468-470 (1994).

121. Sebastian G, Stein A: Das maligne Melanom der Haut. UNI-MED Verlag AG: 16-29 (2000).

122. Seiden MV, Kantoff PW, Krithivas K: Detection of circulating tumor cells in men with localized prostate cancer. *J Clin Oncol* 12: 2634-2639 (1994).

123. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. *Lancet* 338: 1227-1229 (1991).
124. Sonesson B, Eide S, Ringborg U, Rorsman H, Rosengren E: Tyrosinase activity in the serum of patients with malignant melanoma. *Melanoma Res* 5: 113-116 (1995).
125. Stahel RA, Mabry M, Skarkin AT, Speak J, Bernal SD: Detection of bone marrow metastases in small-cell lung cancer by monoclonal antibody. *J Clin Oncol* 3: 455-461 (1985).
126. Stewart CJR, Nandini CL, Richmond JA: Value of A103 (melan-A) immunostaining in the differential diagnosis of ovarian sex cord stromal tumours. *J Clin Pathol* 53: 206-211 (2000).
127. Takahashi K, Isobe T, Ohtsuki Y, Akagi T, Sonobe H, Okuyama T: Immunohistochemical study on the distribution of alpha and beta subunits of S100 protein in human neoplasm and normal tissues. *Virchows Arch Pathol* 45: 385-396 (1984).
128. Tobal K, Sherman LS, Foss AJ, Lightman SL: Detection of melanocytes from uveal melanoma in peripheral blood using the polymerase chain reaction. *Invest Ophthalmol Vis Sci* 34: 2622-2625 (1993).
129. Tomita Y, Takeda A, Okinaga S, Tagami H, Shibahara S: Human oculocutaneous albinism caused by single base insertion in the tyrosinase gene. *Biochem Biophys Res Commun* 164: 990-996 (1989).
130. Tse WT, Forget BG: Reverse Transcription and direct amplification of cellular RNA transcripts by Taq polymerase. *Gene* 88: 293-296 (1990).
131. Van der Velde-Zimmermann D, Poijers JFM, Bouwens-Rombouts A, de Weger RA, de Graaf PW, Tilanus MGJ, van den Tweel JG: Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients. *Am J Pathol* 149: 759-764 (1996).

132. Wakamatsu K, Ito S: Seasonal variation in serum concentration of 5-S-Cysteinyl-dopa and 6-hydroxy-5-methoxy-indole-2-carboxylic acid in healthy Japanese. *Pigment Cell Res* 8: 132-134 (1995).
133. Watson JD, Gilman M, Witkowski J, Zoller M: *Rekombinant DNA*. Spektrum Akademischer Verlag GmbH, Heidelberg, Berlin, Oxford, 2. Auflage (1993).
134. Wicki R, Schäfer BW, Erne P, Heizmann CW: Characterization of the human and mouse cDNAs coding for S100A13, a new member of the S100 protein family. *Biochem Biophys Res Commun* 227: 549-599. (1996).
135. Wittekind C, Tannapfel A: Die Entstehung von Metastasen und ihre Klassifikation. *Strahlenther Onkol* 172: 287-294 (1996).